TABLE 4.
Demographic, clinical, and laboratory parameters of subjects included in the study at 7‐month follow‐up
| Variables | Admission (N = 53) | Follow up (N = 53) | p‐Value |
|---|---|---|---|
| Age | 60.0 (48.0, 66.5) | 60.0 (48.0, 66.5) | 1.000 |
| Ethnicity | |||
| White‐European | 47 (88.6) | N/A | |
| Latin‐American | 3 (5.7) | N/A | |
| African | 2 (3.8) | N/A | |
| Asian‐Far East Asian | 1 (1.9) | N/A | |
| BMI | 28.7 (25.9, 31.4) | 29.8 (26.1, 31.8) | 1.0000 |
| Comorbidities | |||
| CCI | 0.0 (0.0, 1.0) | 0.0 (0.0, 0.0) | 0.0071 |
| CCI‐age | 2.0 (0.0, 3.5) | 2.0 (0.0, 4.0) | 0.0001 |
| CCI (score) | |||
| 0 | 33 (62.3) | 42 (79.3) | 0.0867 |
| 1 | 9 (17.0) | 5 (9.4) | 0.3903 |
| ≥ 2 | 11 (20.7) | 6 (11.3) | 0.2897 |
| Arterial hypertension | 20 (37.7) | Not tested | N/A |
| CRP (mg/L) | 115.8 (20.15, 3.5) | Not tested | N/A |
| Laboratory parameters | |||
| WBC (count/ul) | 7.0 (5.6, 8.6) | 6.2 (5.5, 8.4) | 0.2702 |
| Neutrophils (count/ul) | 5.6 (4.2, 6.5) | 3.6 (2.9, 4.7) | <0.0001 |
| Lymphocytes (count/ul) | 1.0 (0.7, 1.5) | 2.3 (1.9, 2.8) | <0.0001 |
| IL‐6 (pg/ml) | 30.4 (7.72, 83.05) | 27.7 (4.38, 86.5) | 0.5561 |
| IL‐10 (pg/ml) | 4.9 (2.0, 7.9) | 5.6 (3.4, 7.8) | 0.3887 |
| HLA‐G5 (ng/ml) | 324.7 (215.3, 394.5) | <15.0 (< 15.0, < 15.0) | <0.0001 |
| tT (nmol/L) | 2.5 (1.3, 4.4) | 9.8 (3.7, 10.3) | <0.0001 |
| E2 (pg/ml) | 32.48 (17.4, 41.3) | 30.4 (25.4, 35.3) | 0.9807 |
| SARS‐CoV‐2 IgG (AU/ml) | 35.6 (5.5, 105) | 134.0 (87.6, 224.0) | <0.0001 |
Continuous variables are presented as medians (interquartile range); categorical variables are presented as frequency (%). For each variable, the two‐tailed Mann‐Whitney test and Chi Square test were used for testing the difference among groups. Statistically significant p‐values are indicated in bold.
Abbreviations: BMI, Body Mass Index; CCI, Charlson Comorbidity Index; CRP, C‐reactive protein; E2, 17β‐estradiol; tT, total testosterone; WBC, white blood cells.